Pharmaceutical

ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

Shares in the pharma company rose 40% in premarket trading.

May 25, 2024 - 04:00
ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success
Shares in the pharma company rose 40% in premarket trading.
Read the original article

Tags:

Previous Article

ASCO 2024: Merus touts positive Phase II data for head and neck cancer antibody

Next Article

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: After living with sickle cell disease for 39 years, I’m both excited and skeptical about the newly approved gene therapies

Opinion: After living with sickle cell disease for 39 y...

Dec 9, 2023

Despite good data, Ironwood’s shares plummet 

Despite good data, Ironwood’s shares plummet 

Mar 2, 2024

Bristol Myers Squibb reports dip in net income for Q2 2024

Bristol Myers Squibb reports dip in net income for Q2 2024

Jul 30, 2024